


What were the top 20 global M&A transactions of 2012?

12 June 2013 | Analysis | By BioSpectrum Bureau



A majority of life science firms are standing on the edge of the patent cliff and their drug pipelines are experiencing acute scarcity. This is making them seek out partners for mergers & acquisitions (M&A).

Also read:

 $\hat{a} \in \phi$ Why did mergers & acquisitions plunge in APAC? $\hat{a} \in \phi$ What are the key mergers & acquisitions of Q1 2013?

Furthermore, the urge to strengthen their existing product portfolios and enter into new markets has fuelled what can be called the mergers & acquisitions (M&A) galore during the first quarter of 2013. The following have been the 'Top 20 Global M&A Transactions in 2012'.

Top 20 Global Transactions in 2012

Deal Value (\$ bn)	Target	Acquirer	No
	Amylin	BMS	1
	Actavis	Watson	2
	Gen-Probe	Hologic	3
	Human Genome Sciences	GSK	4
0.20 (milest payments t 0	Boston Biomedical	Dainippon	5
	Medicis	Valeant	6
	Inhibitex	Bristol-Myers Squibb	7
	Dako	Agilent	8
1	Par Pharmaceuticals	TPG	9
1	Micromet	Amgen	10
	Fougera	Sandoz	11
1	Ardea	Astrazenea	12
	CSPC NBP Pharmaceutical	CSPC Pharmaceutical Group	13
	Robust Sun	China Pharmaceutical Group	14
j	Enobia	Alexion	15
	One Lamda	Thermo Fisher	16
0.35 (milsest payment v 0	Avila	Celgene	17
(URL Pharma	Takeda	18
(Healthpoint	Smith & Nephew	19
	Becton Dickinson	Corning	20